JP2010173966A - Disintegrable solid preparation - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a disintegrable solid preparation having moderate hardness and exhibiting quick disintegrability in the oral cavity, and also easily producible without undergoing any complicated production process, preferably an intracavity-quick-disintegrable solid preparation (tablet), and further, to provide a composition for the disintegrable solid preparation. <P>SOLUTION: The disintegrable solid preparation includes: (a) trehalose; (b) a crystalline cellulose; (c) an active ingredient; (d) a disintegrant; and (e) a lubricant. In this preparation, the mass ratio of a/b is 100:(11.1-100). <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a disintegrating solid preparation that can be taken without water, preferably a rapidly disintegrating solid preparation (tablet) having a rapid disintegrating property even in the oral cavity. The present invention also relates to a composition for the disintegrating solid preparation.

  In recent years, as an aging society has advanced rapidly, a rapidly disintegrating orally disintegrating tablet that rapidly disintegrates with saliva or a small amount of water has been developed as a dosage form that is easy to take even for patients with weak swallowing power, such as the elderly and children. Has been developed and contributes to the improvement of compliance, such as convenience in the medical field and patient compliance. However, the history of orally disintegrating tablets is short, and there are also technical problems such as disintegration time in the oral cavity, feeling of administration, and ensuring the hardness of tablets that do not break or wear during manufacturing and distribution. Accordingly, development of a technique for producing an orally rapidly disintegrating tablet having an appropriate hardness and rapid disintegration is desired, and an orally disintegrating tablet technique with a higher degree of perfection is expected.

  Patent Document 1 manufactures an orally disintegrating tablet by combining and granulating three components of a saccharide, crystalline cellulose, and a disintegrant, but it is caused by fluidity and disintegration during tableting. No mention is made of the appropriate type of lubricant that affects the particle size, tableting failure, and disintegration of the granulated granules.

  Patent Document 2 specifies a method for producing an orally disintegrating tablet in which two or more carbohydrates are combined. Disintegrants and inorganic excipients are added to composite granules composed of a specific ratio of mannitol and other saccharides, and this also determines the particle size and compression of granulated granules due to fluidity and disintegration during tableting. There is no mention of appropriate types of lubricants that affect tablet disability and disintegration. Also, the active ingredient is not granulated with these excipients.

  In Patent Document 3, the average particle diameter of carbohydrates is defined by two widths, and the average particle diameter at the time of mixing and granulation formed thereby is also defined. However, there is no mention of an appropriate type of lubricant that affects tableting troubles and disintegration during tableting, and all the lubricants in the examples are hydrophobic magnesium stearate.

  Patent Document 4 discloses an excipient that does not contain an active ingredient and has a fast disintegrating property by granulating raw material powder in a specific ratio by combining trehalose, which is a carbohydrate, and cellulose, which is an excipient. It is stated that it will be obtained. Furthermore, although the average particle size of trehalose is specified, there is no mention of the average particle size of granulated granules containing active ingredients, disintegrants, and lubricants. In the examples, all lubricants are hydrophobic. Magnesium distearate and no disintegrant is used.

Japanese Patent Application Laid-Open No. 2005-139086 WO2005 / 037254 JP 2006-70046 specification Japanese Patent Application Laid-Open No. 2001-131091

  The object of the present invention is to provide a disintegrating solid preparation, that is, exhibiting moderate hardness and rapid disintegration in the oral cavity, and can be easily obtained without going through complicated manufacturing steps. It aims at providing the formulation of this. Moreover, it aims at providing the composition for this disintegrating solid formulation.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the component composition used in producing a disintegrating solid preparation includes saccharide trehalose, crystalline cellulose, active ingredient, disintegrant, and lubricant. It was found to be talc of the agent. Then, saccharide trehalose, crystalline cellulose, and active ingredient are mixed and granulated together in advance, and granulated into granules having an average particle size of 50 to 400 μm. Of talc and tableting the mixture. By tableting, an intraoral rapidly disintegrating solid preparation (tablet) showing rapid disintegration in the oral cavity can be obtained.

  Further, by limiting the sugar to trehalose and limiting the blending ratio with crystalline cellulose, a tablet with low impact pressure, high hardness and quick disintegration can be obtained. If the same saccharide mannitol is used in place of trehalose, the moldability is lowered, and as a result, a high compression pressure is required and a rapidly disintegrating tablet cannot be obtained.

  Furthermore, these components are mixed, and the mixture is compressed by a simple method such as tableting with a general granulator or tableting machine without using a special production machine, and molding into a tablet. And a rapidly disintegrating solid preparation (tablet) that exhibits rapid disintegration in the oral cavity.

That is, the present invention is as follows.
(1) Disintegration comprising a) trehalose, b) crystalline cellulose, c) active ingredient, d) disintegrant, and e) lubricant, wherein the mass ratio of a: b is 100: (11.1 to 100). Solid preparation.
(2) The preparation according to (1), wherein the lubricant is talc.
(3) The preparation according to (1), comprising granulated granules comprising a) trehalose, b) crystalline cellulose, and c) an active ingredient.
(4) The preparation according to (3), wherein the granulated granule has an average particle size of 50 to 400 μm.
(5) The preparation according to (1), which is a solid preparation that rapidly disintegrates in the oral cavity.
(6) The preparation according to (1), which does not contain carbohydrate mannitol.
(7) The preparation according to any one of (4) to (6), comprising 0.1 to 10% by mass of a disintegrant based on the mass of the solid preparation.
(8) The preparation according to any one of (4) to (7), comprising 0.1 to 10% by mass of talc with respect to the mass of the tablet solid preparation.
(9) The preparation according to any one of (4) to (8), wherein the push-up load at the preparation preparation is 0.8 kN or less and the stress transmission rate is 90% or less.
(10) A composition for a disintegrating solid preparation comprising a) trehalose, b) crystalline cellulose, d) a disintegrant, and e) a lubricant, wherein the mass ratio of a: b is 100: (11.1 to 100). object.

  The present invention relates to a disintegrating solid preparation that exhibits moderate hardness and rapid disintegration in the oral cavity, preferably a solid preparation (tablet) that rapidly disintegrates in the oral cavity, and is used by elderly people, children, and patients who have difficulty swallowing. Provides fast disintegrating tablets that are easy to take. Moreover, the tablet is an orally disintegrating tablet that can be easily obtained without going through complicated manufacturing steps. Furthermore, the present invention provides a composition for the disintegrating solid preparation.

  The present invention will be specifically described below.

  The disintegrating solid preparation of the present invention, preferably an oral rapid disintegrating solid preparation (tablet), is a pharmaceutical preparation that can be taken without water, and has rapid disintegrating properties in the oral cavity. It consists of crystalline cellulose, active ingredient, disintegrant, and lubricant talc.

  The disintegrating solid preparation referred to in the present invention, preferably a solid preparation (tablet) rapidly disintegrating in the oral cavity, may contain components other than trehalose, crystalline cellulose, active ingredient, disintegrant, and lubricant talc. Examples of such components include other excipients, disintegrants, binders, fluidizers, lubricants, flavoring agents, fragrances, colorants, sweeteners, surfactants, and the like. Excipients include sugars such as sucrose, glucose, lactose, fructose and maltose, sugar alcohols such as xylitol, maltitol and sorbitol, starches such as rice starch, wheat starch, corn starch and potato starch, hydrogen phosphate Examples thereof include inorganic substances such as calcium, calcium carbonate, anhydrous silicic acid, hydrous silicic acid, aluminum silicate, and magnesium aluminate silicate. Examples of disintegrants include croscarmellose sodium, carmellose calcium, carmellose, celluloses such as low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, hydroxypropyl starch, starches such as partially pregelatinized starch, and crospovidone. It is done. Binders include water-soluble polysaccharides such as gelatin, pullulan, carrageenan, xanthan gum, tamarind gum, pectin, sodium alginate and gum arabic, celluloses such as hydroxypropylcellulose, hydroxypropylmethylcellulose and methylcellulose, pregelatinized starch, starch paste And synthetic polymers such as polyvinylpyrrolidone, carboxyvinyl polymer, and polyvinyl alcohol. Examples of the fluidizing agent include hydrous silicon dioxide and light anhydrous silicic acid. Examples of the corrigent include glutamic acid, fumaric acid, succinic acid, citric acid, sodium citrate, tartaric acid, malic acid, ascorbic acid, sodium chloride, 1-menthol and the like. Examples of the fragrances include orange, vanilla, strawberry, yogurt, menthol and the like. Examples of the colorant include food colors such as food red No. 3, food yellow No. 5, and food blue No. 1, and riboflavin. Examples of sweeteners include aspartame, saccharin, dipotassium glycyrrhizinate, stevia and the like. Examples of the surfactant include phospholipid, glycerin fatty acid ester, polyethylene glycol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, and the like.

  Trehalose used in the present invention is a non-reducing disaccharide in which glucose is α-1,1-bonded, and is a white crystal or non-crystalline powder, has no smell, and has a sweet taste. As commercial products, trehalose G, SG (Hayashibara Biochemical Laboratories), trehalose P, G (Asahi Kasei Chemicals) and the like can be used.

  The crystalline cellulose used in the present invention is a white crystalline powder, which is obtained by partially depolymerizing and purifying α-cellulose obtained as a pulp from a fibrous plant with a mineral acid. Although there are various grades of crystalline cellulose, in the present invention, the bulk density, which is the powder physical property value of highly moldable crystalline cellulose, is 0.2 g / ml, the average particle size is 50 μm, and the angle of repose is 50. °, a crystalline cellulose having an average particle diameter major axis / minor axis ratio (L / D) of 2.5 to 4.0. As a commercially available product, Theolas KG-802 (trade name) (Asahi Kasei Chemicals) and the like can be used.

  The active ingredient used in the present invention is used for the treatment, prevention and diagnosis of human and animal diseases, and is not an instrument / machine. Examples thereof include an antidepressant (phenytoin). , Acetylphenetride, trimetadione, phenobarbital, primidone, nitrazepam, sodium valproate, sultiam, etc.), antipyretic analgesics (acetaminophen, phenylacetylglycine methylamide, mefenamic acid, diclofenac sodium, fructophenine, aspirin, aspirin aluminum Ethenzamid, oxyphenbutazone, sulpyrine, phenylbutazone, ibuprofen, alclofenac, naloxene, ketoprofen, tinolidine hydrochloride, benzydamine hydrochloride, thiaramide hydrochloride, indomethacin, piroxicam, Ritylamide, etc.), antipruritics such as dimenhydrinate, meclizine hydrochloride, diphenidol hydrochloride, narcotics (opium alkaloid hydrochloride, morphine hydrochloride, codeine phosphate, dihydrocodeine phosphate, oxymethebanol, etc.), for neuropsychiatric use Agents (chlorpromazine hydrochloride, levomepromazine maleate, perazine, maleic acid, periciazine, perphenazine, chlorprothixene, haloperidol, diazepam, oxazepam, oxazolam, mexazolam, alprazolam, zotepine, etc.), skeletal muscle relaxants (chlorzoxazone, carbamine) Chlorphenesin acid, chlormezanone, pridinol mesylate, eperisone hydrochloride, etc.), agents for autonomic nerves (betanecol chloride, neostigmine bromide, pyridostigmine bromide, etc.), antispasmodics (sulfuric acid Lopin, butropium bromide, butylspocholamine bromide, propantheline bromide, papaverine hydrochloride, etc.), antiparkinsonian (biperiden hydrochloride, trihexyphenidyl hydrochloride, amantadine hydrochloride, levodopa, etc.), antihistamines (diphenhydramine hydrochloride, dl) -Chlorpheniramine maleate, promethazine, mequitazine, clemastine fumarate, etc., cardiotonic agents (aminophylline, caffeine, dl-isoproterenol hydrochloride, ethylephrine hydrochloride, norphenelin hydrochloride, ubidecarenone, etc.), arrhythmic agents (procainamide hydrochloride) , Pindolol, metoprolol tartrate, disoviramide, etc.), diuretics (potassium chloride, cyclopenthiazide, hydrochlorothiazide, triamterene, acetazolamide, furosemide, etc.), antihypertensive agents (hexyl bromide) Sametonium, hydralazine hydrochloride, silosingopine, reserpine, propranolic hydrochloride, captopril, methyldopa, etc.), vasoconstrictor (dihydroergotamine mesylate, etc.), vasodilator (etaphenone hydrochloride, diltiazem hydrochloride, carbochromen hydrochloride, pentaerythritol tetranitrate, Dipyridamole, isosorbide nitrate, nifedipine, nicamethate citrate, cyclandrate, cinnarizine, etc., arteriosclerotic agents (ethyl linoleate, lecithin, clofibrate, etc.), circulatory organ agents (nicardipine hydrochloride, meclofenoxate hydrochloride) , Cytochrome C, pyridinol carbamate, pinbocetin, calcium hopantenate, pentoxifylline, idebenone, etc.), respiratory stimulant (dimephrine hydrochloride, etc.), antitussive expectorant (codeine phosphate) Dihydrocodeine phosphate, dextromethorphan hydrobromide, noscapine, L-methylcysteine hydrochloride, bromhexine hydrochloride, theophylline, ephedrine hydrochloride, amlexanox, etc.), abdomen (osalmide, phenylpropanol, hymechromone, etc.), intestinal (chloride) Berberine, loperamide hydrochloride, etc.), digestive organs (metoclopramide, phenipentol, domperidone, etc.), vitamins (retinol acetate, dihydrotaxosterol, etretinate, thiamine hydrochloride, thiamine nitrate, fursultiamine, octothiamine Chicotiamine, riboflavin, pyridoxine hydrochloride, pyridoxal phosphate, nicotinic acid, pantethine, cyanocobalamin, biotin, ascorbic acid, phytonadione, menatetrenone, etc.), antibiotics ( Benzylpenicillin benzathine, amoxicillin, ampicillin, cyclacillin, cefaclor, cephalexin, cefuroxime axetil, erythromycin, kitasamycin, josamycin, chloramphenicol, tetracycline, griseofulvin, cefzonam sodium, etc.), chemotherapeutic agent (sulfa Methoxazole, isoniazid, etionamide, thiazosulfone, nitrofurantoin, enoxacin, ofloxacin, norfloxacin, etc.).

  A composition containing no active ingredient (c), that is, a) trehalose, b) crystalline cellulose, d) a disintegrant, and e) a lubricant, wherein the mass ratio of a: b is 100: (11.1-100) ) Can be used as an excipient for the disintegrating solid preparation of the present invention.

  Examples of the disintegrant used in the present invention include potato starch, corn starch, partially pregelatinized starch, starch, sodium carboxymethyl starch, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, carboxymethylcellulose, crospovidone, carmellose, Although carmellose sodium, carmellose calcium, etc. are mentioned, crospovidone (polyplastidone XL-10: ISP) is more preferable.

  Lubricant talc used in the present invention is a white to off-white fine crystalline powder containing natural hydrous magnesium silicate and a small amount of aluminum silicate. Commercially available products include Talkan Hayashi (trade name) (Hayashi Kasei), talc (Nippon Talc, Fuji Talc, Oriental Pharmaceutical, Tsuchiya Kaolin).

  Originally, a lubricant is blended for the purpose of preventing powder adhering to a mortar and pestle when producing tablets, but if the lubrication effect is too strong, the moldability becomes weak and a practical tablet hardness of 40 Excessive pressure must be applied to obtain ~ 60N. Tablets produced at a high pressure tend not to be suitable for orally disintegrating tablets because the disintegration rate of the tablets tends to be delayed. Therefore, it is necessary to produce the tablets at the lowest possible pressure. In that respect, although there are many types of lubricants, talc with low lubrication effect is preferable, and hydrophilic talc is more preferable. The blending amount of talc is preferably 0.1 to 10.0% by mass relative to the tablet weight, and more preferably 0.1 to 5.0% by mass in order to suppress the lubrication effect. Moreover, it is preferable that the push-up load and stress transmission rate at the time of tablet preparation are reduced by blending talc, the push-up load is 0.10 to 0.80 kN, and the stress transfer rate is 30.0 to 90.0%. More preferably, the lifting load is 0.20 to 0.60 kN, and the stress transmissibility is 40.0 to 80.0%.

  The push-up load and stress transmission rate are the pressures measured when producing tablets. The measuring instrument uses Tabflex (trade name) (Okada Seiko), and the lower punch pushes up the tablets and discharges them. The load when it is applied is the lifting load. When the push-up load is large, the tablet is not easily separated and tends to cause a tableting failure. In addition, the stress transmissibility is a value obtained by measuring the load on the upper and lower eyelids necessary for tablet production and dividing the value of the lower eyelid load by the upper eyelid load value as a percentage, and this value is large. And the void ratio in the tablet is lowered, and the disintegration property of the tablet tends to deteriorate.

  The mass ratio of trehalose and crystalline cellulose is preferably trehalose: crystalline cellulose = 100.0: (11.1 to 100.0), preferably 100.0, from the hardness of tablet, disintegration property, sweetness in mouth and texture. : (25.0-70.0) is more preferable. When the mass ratio of the crystalline cellulose is 100.1% by mass or more with respect to trehalose, the texture in the oral cavity is insufficient and the sweetness is insufficient, which is not suitable for an orally disintegrating tablet. On the other hand, if it is 11.0% by mass or less, the moldability is poor and a high pressure is required at the time of tablet production, and as a result, the disintegration property of the tablet is affected.

  The active ingredient is mixed with the mixed powder in which the mass ratio of trehalose and crystalline cellulose is trehalose: crystalline cellulose = 100.0: (11.1 to 100.0), and the granulated granules are mixed and granulated. However, the production method of mixing and granulation will be described. As a mixing method, an apparatus usually used for producing pharmaceuticals is used, and examples thereof include a V-type mixer, a double cone type mixer, and a tumbler type mixer (Dalton). In the granulation method, water is added to or sprayed on the mixed powder flowing in the granulator to produce granulated granules. The granulator is composed of a fluidized bed granulator (Freund), high-speed stirring granulation. Machine (Pauleck). The blending ratio of the active ingredient in the mixed powder is preferably 70.0% by mass or less, more preferably 50.0% by mass or less, based on the mixed powder of trehalose and crystalline cellulose. If the blending ratio of the active ingredient in the mixed powder is 70.0% by mass or less, blending of the active ingredient does not affect the moldability and disintegration of the tablet, and the speed as an orally disintegrating tablet. There is no tendency to impair the disintegrating function.

  Drying methods for granulated granules include blow drying and hot air drying. As drying equipment, fluidized bed dryers (flow coater (trade name); Freund, multiplex (trade name); Paulek) and box-type hot air circulation type Examples thereof include a dryer and a shelf dryer.

  In order to adjust the size of the granule, the dried granulated granule is preferably prepared so as to have an average particle size of 50 to 400 μm with a granulator, and more preferably 50 to 300 μm. Examples of the sizing device include an oscillator and a comil.

  The disintegrant is blended in order to improve the disintegration property of the tablet, but the blending method is preferably blended into the granulated granule. It is preferable to add a disintegrant to the granulated granule because the disintegration property is not impaired. 0.1-10.0 mass% is preferable with respect to tablet weight, and, as for the compounding quantity of a disintegrating agent, 0.1-5.0 mass% is more preferable. If it is 10.0 mass% or less, since it does not affect the moldability of a tablet, it is suitable for an orally disintegrating tablet.

  As a tableting method for producing tablets, mixed powder is filled and compression-molded to produce tablets. As a tableting device, a rotary tableting machine (Libra 2 (trade name); Kikusui Seisakusho) is generally used. Can be mentioned. The feeder part which supplies powder to a die can select the kind of feeders, such as a stirring feeder and an open feeder, from the fluidity | liquidity of powder and the magnitude | size of a granule.

  The present invention will be described based on examples.

The physical property measurement methods and conditions used in the present application are as follows.
<Average particle diameter of granulated granule [μm]>
The particle size distribution was measured by sieving 20 g of a sample using a JIS standard sieve for 15 minutes with a low tap type sieve shaker (manufactured by Hiraiko Seisakusho, type A sieve shaker). And the integrated 50 mass% particle diameter in sieving integrated distribution was made into the average particle diameter.
<Tablet disintegration test>
The test was carried out in accordance with the 15th revision Japanese Pharmacopoeia, General Test Method "Disintegration Test Method". Water was used as the test solution.
<Tablet oral disintegration test>
Using three healthy adult male subjects as subjects, the time required for the tablet to completely disintegrate with saliva in the oral cavity was measured. Each person was measured twice and the average value of 3 persons was used.
<Tablet friability test>
Fifteenth revised Japanese Pharmacopoeia, in accordance with the General Rules for Preparation. Twenty tablets were placed in a cylinder rotating at a constant speed of 25 rpm, and dropping of the tablets was repeated with an intermediate plate. The tablet was rotated for 4 minutes and the tablet in the cylinder was taken out. The broken powder and small particles were removed by sieving and the mass was measured, and the mass loss was expressed as a percentage of the original mass.
<Push-up load, stress transmission rate>
The mixed powder was charged into Tabflex (trade name) (Okada Seiko), and the push-up load and stress transfer rate necessary for tablet production were measured under the following conditions.
(1) Tablet weight: 180mg
(2) Tablet diameter: 8mmφ
(3) Filling depth: 15mm
(4) Tableting pressure: 4.0kN
[Example 1]
Trehalose P (Asahi Kasei Chemicals), 0.56 kg and crystalline cellulose Theolas KG-802 (trade name) (Asahi Kasei Chemicals), 0.24 kg and acetaminophen (API), 0.80 kg of tumbler mixer (TM-50S) The mold was put into a mold (Dalton), mixed for 20 minutes, then taken out, put into a high-speed agitation granulator (vertical granulator VG-10; Powrec), and granulated. The granulation conditions were as follows.

(1) Broad rotation speed: 500rpm
(2) Chopper rotation speed: 1500rpm
(3) Granulation time: 3 minutes (4) Amount of water added: 0.24 kg
The granulated granules were taken out and charged into a fluidized bed dryer, and the granules were dried. Drying conditions were as follows.

(A) Equipment used: Multiplex (trade name), MP-01 type, POWREC Co., Ltd.
(B) Air volume: 7 m ³ / min
(C) Supply air temperature: 70 to 75 ° C
(D) Stop exhaust temperature: 45 ° C
The dried granules were taken out and sized with a sieve mesh of 710 μm, and the particle size distribution of the granules was measured. As a result, the average particle size was 352.5 μm.

  36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out.

  As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and the stress transmission rate necessary for tablet production, the pushing load was 0.487 kN and the stress transmission rate was 74.5%. The measurement conditions of Tabflex (trade name) were as follows.

(1) Tablet weight: 180mg
(2) Tablet diameter: 8mmφ
(3) Filling depth: 15mm
The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho) to prepare tablets. The tableting conditions were as follows. Tableting can be performed without any tableting troubles. The hardness of the obtained tablet is 44 N, disintegration time by disintegration test is 14 seconds, disintegration time in the oral cavity is 16 seconds, and friability is 0.09%. Sufficient results were obtained as a tablet.

(I) Tablet weight: 180mg
(B) Tablet diameter: 8mmφ
(C) Rotor rotation speed: 45 rpm
(D) Feeder type: Open feeder (e) Tableting pressure: 3.6 kN
(F) Tableting time: 10 minutes (g) Number of mortars: 12 [Example 2]
A granulated granule having an average particle diameter of 165.0 μm was prepared in the same manner as in Example 1 except that the granulator was a fluidized bed granulator (multiplex (trade name) MP-01 type; Powrec). Obtained. 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.628 kN and the stress transmission rate was 80.3%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 4.2 kN. Tablets can be compressed without any obstruction, and the tablet hardness is 45N, disintegration time by disintegration test is 18 seconds, disintegration time in the oral cavity is 21 seconds, and friability is 0.12%. Sufficient results were obtained as a tablet.
[Example 3]
Trehalose P (Asahi Kasei Chemicals), 0.72 kg and crystalline cellulose Theolas KG-802 (trade name) (Asahi Kasei Chemicals), 0.08 kg and acetaminophen (API), 0.80 kg of tumbler mixer (TM-50S Except for charging into a mold (Dalton), the same operation as in Example 1 was carried out to obtain granulated granules having an average particle size of 366.2 μm. 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.567 kN and the stress transmission rate was 77.8%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 4.2 kN. Tablets can be compressed without any obstruction, and the hardness of the obtained tablets is 45N, disintegration time by disintegration test is 17 seconds, disintegration time in the oral cavity is 19 seconds, and friability is 0.13%. Sufficient results were obtained as a tablet.
[Example 4]
Trehalose P (Asahi Kasei Chemicals), 0.40 kg and crystalline cellulose Theolas KG-802 (trade name) (Asahi Kasei Chemicals), 0.40 kg, acetaminophen (API), 0.80 kg of tumbler mixer (TM-50S Except for charging to a mold (Dalton), the same operation as in Example 1 was performed to obtain granulated granules having an average particle diameter of 278.4 μm. 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.455 kN and the stress transmission rate was 72.7%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and tablets were produced at a tableting pressure of 4.0 kN. Tablets can be compressed without any obstruction, and the tablet hardness is 46N, disintegration time by disintegration test is 15 seconds, disintegration time in the oral cavity is 16 seconds, and friability is 0.07%. Sufficient results were obtained as a tablet.
[Example 5]
In the same manner as in Example 1, granulated granules having an average particle size of 352.5 μm were obtained. Crospovidone and 36 g were added to 1200 g of the granule, charged in a tumbler mixer (TM-50S type; Dalton), and mixed for 20 minutes. Then, 1.2 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.507 kN and the stress transmission rate was 77.9%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 3.3 kN. Tablets can be compressed without any obstruction, and the obtained tablet has a hardness of 43N, disintegration time by disintegration test is 15 seconds, disintegration time in the oral cavity is 18 seconds, and friability is 0.09%. Sufficient results were obtained as a tablet.
[Example 6]
In the same manner as in Example 1, granulated granules having an average particle size of 352.5 μm were obtained. 36 g of crospovidone was added to 1200 g of the granule, charged in a tumbler mixer (TM-50S type; Dalton), mixed for 20 minutes, 120 g of talc was added, and the mixture was further mixed for 5 minutes and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.422 kN and the stress transmission rate was 65.6%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 4.7 kN. Tablets can be compressed without any obstruction, and the hardness of the obtained tablets is 44N, disintegration time by disintegration test is 25 seconds, disintegration time in the oral cavity is 30 seconds, and friability is 0.11%. Sufficient results were obtained as a tablet.
[Comparative Example 1]
In the same manner as in Example 1, granulated granules having an average particle size of 352.5 μm were obtained. After adding 36 g of crospovidone to 1200 g of this granule, charging into a tumbler mixer (TM-50S type; Dalton) for 20 minutes, adding 12 g of magnesium stearate instead of lubricant talc, adding 5 Mix for minutes and remove. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.184 kN and the stress transmission rate was 91.0%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and tablets were produced at a tableting pressure of 6.6 kN. The tablets obtained had a hardness of 47 N, a disintegration time by disintegration test of 259 seconds, and a friability of 0.18%. By using magnesium stearate, the lubrication effect became stronger, resulting in higher tableting pressure and delayed tablet disintegration time. It was unsuitable as an orally disintegrating tablet.
[Comparative Example 2]
Trehalose P (Asahi Kasei Chemicals), 0.38 kg and crystalline cellulose Theolas KG-802 (trade name) (Asahi Kasei Chemicals), 0.42 kg, acetaminophen (API), 0.80 kg of tumbler mixer (TM-50S Except for charging into a mold (Dalton), the same operation as in Example 1 was carried out to obtain granulated granules having an average particle size of 315.3 μm. 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.655 kN and the stress transmission rate was 76.7%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and tablets were produced at a tableting pressure of 3.0 kN. The tablets obtained had a hardness of 45N, a disintegration time of 17 seconds according to the disintegration test, a disintegration time in the oral cavity of 18 seconds, and a friability of 0.07%, and a satisfactory disintegration time as an orally disintegrating tablet was obtained. However, the rough feeling of crystalline cellulose is in the oral cavity, and when considering long-term administration, it was unsuitable as an orally disintegrating tablet.
[Comparative Example 3]
Trehalose P (Asahi Kasei Chemicals), 0.76 kg and crystalline cellulose Theolas KG-802 (trade name) (Asahi Kasei Chemicals), 0.04 kg and acetaminophen (API), 0.80 kg of tumbler mixer (TM-50S) Except for charging into a mold (Dalton), granulated granules having an average particle diameter of 390.5 μm were obtained in the same manner as in Example 1. 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.750 kN and the stress transmission rate was 88.5%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 9.0 kN. The tablets obtained had a hardness of 42 N, a disintegration time of 125 seconds as determined by the disintegration test, and a friability of 0.14%. Thus, a satisfactory disintegration time was not obtained. Furthermore, some tableting troubles such as sticking occurred, and it was unsuitable as an orally disintegrating tablet.
[Comparative Example 4]
A granulated granule having an average particle diameter of 340.2 μm was obtained in the same manner as in Example 1 except that trehalose (a) was changed to mannitol (f). 36 g of crospovidone was added to 1200 g of these granules, charged in a tumbler mixer (TM-50S type; Dalton) and mixed for 20 minutes, then 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and the stress transmission rate necessary for tablet production, the pushing load was 0.367 kN and the stress transmission rate was 70.8%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and a tablet was produced at a tableting pressure of 7.2 kN. The tablets obtained had a hardness of 46 N, a disintegration time of 76 seconds, a disintegration time in the oral cavity of 85 seconds, and a friability of 0.16%. Thus, a satisfactory disintegration time was obtained as an orally disintegrating tablet. I couldn't.
[Comparative Example 5]
In the same manner as in Example 1, granulated granules having an average particle size of 352.5 μm were obtained. 36 g of crospovidone was added to 1200 g of this granule, charged into a tumbler mixer (TM-50S type; Dalton), and mixed for 20 minutes. Then, 12 g of talc was added, mixed for another 5 minutes, and taken out. As a result of charging the taken-out mixed powder into Tabflex (trade name) and measuring the pushing load and stress transmission rate necessary for tablet production, the pushing load was 0.855 kN and the stress transmission rate was 92.1%. The mixed powder was charged into a tableting machine (Libra 2 (trade name); Kikusui Seisakusho), and tablets were produced at a tableting pressure of 7.5 kN. The tablets obtained had a hardness of 73 N, a disintegration time by disintegration test of 195 seconds, and a friability of 0.04%. By increasing the tableting pressure, the tablet hardness also increased. As a result, the disintegration time of the tablet was delayed, making it unsuitable as an orally disintegrating tablet.

  The present invention can be suitably used in the field of pharmaceutical preparations containing pharmaceutical drugs. Since it has a particularly excellent disintegration property, it can be used as a disintegrating solid preparation that can be taken without water, preferably as a solid preparation (tablet) that is rapidly disintegrating in the oral cavity.

Claims (10)

  A disintegrating solid preparation comprising a) trehalose, b) crystalline cellulose, c) active ingredient, d) disintegrant, and e) lubricant, wherein the mass ratio of a: b is 100: (11.1 to 100). .   The preparation according to claim 1, wherein the lubricant is talc.   The formulation according to claim 1, comprising granulated granules comprising a) trehalose, b) crystalline cellulose, and c) an active ingredient.   The preparation according to claim 3, wherein the granulated granules have an average particle size of 50 to 400 µm.   The preparation according to claim 1, which is a solid preparation rapidly disintegrating in the oral cavity.   The preparation according to claim 1, which does not contain carbohydrate mannitol.   The formulation as described in any one of Claims 4-6 which contains 0.1-10 mass% of disintegrating agents with respect to the mass of a solid formulation.   The formulation as described in any one of Claims 4-7 which contains 0.1-10 mass% of talc with respect to the mass of a tablet solid formulation.   The preparation according to any one of claims 4 to 8, wherein the push-up load at the preparation preparation is 0.8 kN or less and the stress transmission rate is 90% or less.   A composition for a disintegrating solid preparation comprising a) trehalose, b) crystalline cellulose, d) a disintegrant, and e) a lubricant, wherein the mass ratio of a: b is 100: (11.1 to 100).